Swollen Knee Treatment Market Size was valued at USD 1.28 Billion in 2023. The Global Swollen Knee Treatment industry is projected to grow from USD 1.35 Billion in 2024 to USD 2.12 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.93% during the forecast period (2024 - 2032).
Nobody must sacrifice their preferred pastime or struggle daily because of chronic knee pain in July 2023. Kneeflow is being launched, a three-in-one massager that can be used by anyone who suffers from knee pain and mobility issues. It is a personal home massage tool for relief, prevention, and recovery from knee surgery, as well as any tenderness experienced after exercise. The symptoms of chronic knee pain typically include discomfort, stiffness, inflammation, and joint degradation. Pharmaceutical relief for pain therapies, physical therapy, steroid shots, and surgery are some of the options that patients often resort to; they are costly remedies that do not stop an ongoing degeneration of joint tissues. Kneeflow has a touch screen LCD (Liquid Crystal Display), which is simple to use with the compact size that makes it portable, and alongside this, it’s cordless.
The Endo International plc (NASDAQ: ENDP) on June 30th, 2022, indicates that a subsidiary, Endo Ventures Limited (EVL), has completed a deal with Taiwan Liposome Company Ltd (TLC) to commercialize TLC599, which is an investigational product of TLC.TLC599 is a combination therapy currently in Phase 3 development as an injectable for the treatment of osteoarthritis knee pain. The agreement states that the major role of EVL will be regulatory approval, while product development will be left mainly to TLC and marketing in the United States. Endo is expected to distribute the product exclusively upon approval by the relevant regulatory authorities.
In August 2019, Bioventus, a global leader in orthobiologic solutions, announced plans to introduce DUROLANE SJ(1mL) and received extended recommendations on DUROLANE(3mL), its single-shot jointfluid osteoarthritis (OA)treatment in Australia and New Zealand. Both are hyaluronic acid (HA)--based products and are available from LMT Surgical. In general, DUROLANE SJ (1mL) has been cleared by the Therapeutic Goods Administration (TGA)of Australia and MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority, and it will launch later this year. It should only be used for relieving mild to moderate OA-associated pains in the ankle, elbow, wrist, fingers, and toes. Also, DUROLANE SJ(1mL) is indicated for postoperative pain following joint arthroscopy due to joint arthritis up until three months after surgery.
Knee swelling or occasionally mentioned as “water on the knee” is a condition where excess fluid gets accumulated in an around the knee joint. This conditions in medical terms are referred to as “knee effusion”. The swollen knee can result due to injuries such as torn ligament, cartilage tear or broken bones. The increasing number of geriatric populations followed by the rising frequency of musculoskeletal diseases, a growing number of surgeries undertaken is projected to grow the swollen knee treatment market. The operating procedure of knee replacement is inclusive of various steps taken to implant the artificial device and replacement of the damaged knee.
The swollen knee treatment market is anticipated to grow due to several factors such as the growing rate of elderly aged diseases like obesity, arthritis, osteoporosis, diabetes and sports-related injuries. Contrary, due to existing and upcoming advance technologies such as minimally invasive surgery and improved implant supplies are making it more broadly accepted even by the younger population.
In spite of being a widely used technique for curing extremely debilitating diseases, such as rheumatoid arthritis, the swollen knee treatment market is confronting some challenges such as financial slowdown which is avoiding the growth of the market. Other growth restraining factors of the swollen knee treatment market are intense competition, huge surgical cost, growing awareness for some non-surgical treatment methods such as exercises, shoe inserts, walking aids, weight loss programs, and painkiller medicines.
The swollen knee treatment market has been segmented on the basis of type and end-users.
On the basis of type, the market has been classified as medications, patient-controlled analgesia (PCA) pumps, nerve blocks, liposomal bupivacaine, and surgery. The medications have been segmented into opioids and corticosteroids and others. The surgery is segmented into arthrocentesis, arthroscopy and knee replacement. The knee replacement is further segmented into total knee replacement, unicompartmental knee replacement, and others.
On the basis of end-users, the market has been classified as hospitals, clinics, ambulatory surgery centers, and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
The European swollen knee treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The swollen knee treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The swollen knee treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.
In the swollen knee treatment market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies, the rise in awareness, the rise in growth of the healthcare sector, and due to favorable compensation setting for many surgical procedures.
The European market is expected to hold the second largest market share. The market growth in this region can be attributed to the rising frequency of diabetes patients, increasing number of surgeries, and increasing demand for advanced treatment procedures are boosting the European market.
The market share in Asia-Pacific is also projected to experience growth in the near future due to access to optimal treatment facilities and growing demand for advanced technology, better adoption rate, increase in disposable income, and rising medical tourism.
The market in the Middle East and Africa is expected to account for the smallest share of the swollen knee treatment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Key Players
Intended Audience
| Report Attribute/Metric | Details |
| Market Size | 2032: 2.12 |
| CAGR | 2024-2032: 4.93% CAGR |
| Base Year | 2021 |
| Forecast Period | 2024-2032 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Basis of type and End-users |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Stryker Corporation, Zimmer Holdings, Smith & Nephew Plc., DePuy Companies Inc., Wright Medical Group Inc., Biomet Inc., Exactech, B. Braun Melsungen AG, Pfizer Pharmaceuticals Inc., Merck & Co., Fresenius Kabi, AngioDynamics, C.R.Bard ,Teleflex ,Smiths Medical. |
| Key Market Opportunities | · Rising frequency of musculoskeletal diseases · A growing number of surgeries |
| Key Market Drivers | · Growing rate of elderly aged diseases like obesity, arthritis, osteoporosis, diabetes · Sports-related injuries |
Frequently Asked Questions (FAQ) :
Swollen knee treatment market would be restrained by huge surgical cost, awareness of non-surgical treatment methods, such as exercises, weight loss programs, walking aids, shoe inserts, and painkiller medicines.
Swollen knee treatment market patient-controlled analgesia (PCA) pumps, medications, liposomal bupivacaine, nerve blocks, and surgery.
Swollen knee treatment market would include clinics, ambulatory surgery centers, hospitals, and others.
The companies are Zimmer Holdings, Stryker Corporation, DePuy Companies Inc., Smith & Nephew Plc., Biomet Inc., Wright Medical Group Inc., B. Braun Melsungen AG, Exactech, Merck & Co., Pfizer Pharmaceuticals Inc., AngioDynamics, C.R.Bard , Fresenius Kabi, Teleflex, and Smiths Medical.
North America is the largest swollen knee treatment market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
